TNDM TANDEM DIABETES CARE INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1438133 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.8%
TTM net income YoY75.8%
TTM EPS YoY76.4%
Revenue 3-yr CAGR11.7%
Net income 3-yr CAGR—
Margins
Gross margin56.6%
Operating margin-2.4%
Net margin-4.6%
FCF margin-3.4%
EBITDA margin-0.7%
Returns
ROE-36.7%
ROA-4.8%
ROIC (approx.)-3.9%
Asset turnover1.06x
Leverage & solvency
Liabilities / assets88.3%
Debt / equity4.47x
Current ratio3.21x
Interest coverage-2.80x
Cash quality & payout
Operating cash flow / net income0.30x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.01B | $940.20M |
| Cost of revenue | $468.72M | $450.63M |
| Gross profit | $546.01M | $489.57M |
| R&D expense | $193.11M | $198.88M |
| SG&A expense | $444.99M | $389.82M |
| Operating income | -$187.26M | -$99.13M |
| Interest expense | $7.91M | $7.42M |
| Pretax income | -$200.27M | -$91.87M |
| Income tax | $4.44M | $4.16M |
| Net income | -$204.71M | -$96.03M |
| EBITDA | -$169.59M | -$82.52M |
| EPS (basic) | -3.04 | -1.47 |
| EPS (diluted) | -3.04 | -1.47 |
| Weighted avg. shares (diluted) | 67.28M | 65.45M |
| Balance sheet | ||
| Cash & equivalents | $90.63M | $69.23M |
| Short-term investments | $202.03M | $369.10M |
| Receivables | $165.49M | $114.58M |
| Inventory | $128.77M | $149.61M |
| Current assets | $618.14M | $724.49M |
| PP&E, net | $83.58M | $78.15M |
| Intangibles | $11.72M | $925,000 |
| Total assets | $881.11M | $967.66M |
| Current liabilities | $242.72M | $247.05M |
| Short-term debt | — | $40.67M |
| Long-term debt | $310.04M | $308.27M |
| Total debt | $310.04M | $348.94M |
| Total liabilities | $725.94M | $704.56M |
| Shareholders' equity | $155.17M | $263.10M |
| Net debt | $219.40M | $279.70M |
| Shares outstanding | 68.29M | 66.26M |
| Cash flow statement | ||
| Operating cash flow | -$9.72M | $24.23M |
| Capital expenditure | $19.95M | $19.23M |
| Free cash flow | -$29.67M | $4.99M |
| Investing cash flow | $72.88M | -$23.48M |
| Financing cash flow | -$43.37M | $8.37M |
| Depreciation & amortization | $17.67M | $16.61M |
| Stock-based compensation | $92.38M | $101.38M |
| Share buybacks | $0 | $30.00M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.